French health tech startup specialising in remote monitoring and therapeutic follow-up of cancer patients, Resilience has announced €40 million funding in a Series A. The funding will enable the platform to accelerate the deployment of its medical devices (CE Class IIa) in healthcare institutions and enrich its application with new functionalities dedicated to the wellbeing of patients.
The round was led by Cathay Innovation, a global venture capital fund with a track record in digital health, with strong support from Singular, the French investment fund which had participated earlier in the first €5 million round in March 2021. Other prestigious investors such as Exor Seeds, Picus Capital, and Seaya Ventures also participated along with a consortium of well-recognised players in the healthcare sector, including Fondation Santé Service, MACSF, Ramsay Santé, and Vivalto Ventures.
The platform which wants to help cancer treatment institutes as well as cancer patients at every step of the treatment journey also plans to create a foundation to fund research projects that improve patients’ adherence to treatment and their quality of life.
Co-founded less than a year ago by two tech entrepreneurs, Céline Lazorthes and Jonathan Benhamou, in partnership with the Gustave Roussy Institute, the fifth largest cancer center in the world, the startup had raised €5 million in 2021.
Regarding how the startup is reinventing patient care, Jonathan Benhamou and Céline Lazorthes, Co-founders of Resilience said: "We are deeply convinced, as proven by the CAPRI study, of the contribution of remote patient monitoring in oncology. We want to accelerate its adoption in health institutions and thus, quickly allow patients to benefit from a better adapted and a more humane follow-up."
"Through its innovative technologies to improve patient’s quality of life and the effectiveness of therapeutic treatments, Resilience is starting a profound transformation in the fight against cancer. Our investments in digital health over years have proven to us the necessity to reinvent cancer care," said Jacky Abitbol, Managing Partner at Cathay Innovation.